EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
NICE backs funding for Kyowa Kirin’s bone disorder drugChildren in England and Wales with a rare inherited disorder causing soft and weak bones can have access Share XNICE backs funding for Kyowa Kirin’s bone disorder drughttps://pharmaphorum.com/news/nice-backs-funding-for-kyowa-kirins-bone-disorder-drug/
